Daniel Busby
Stock Analyst at RBC Capital
(1.21)
# 2,804
Out of 4,667 analysts
6
Total ratings
50%
Success rate
-8.02%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Daniel Busby
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRCA Verrica Pharmaceuticals | Downgrades: Sector Perform | $16 → $4 | $0.99 | +304.04% | 2 | May 25, 2022 | |
| PFE Pfizer | Maintains: Sector Perform | $43 → $44 | $25.13 | +75.09% | 1 | Jun 17, 2021 | |
| MNKD MannKind | Initiates: Sector Perform | $5 | $6.90 | -27.54% | 2 | May 14, 2021 | |
| ABBV AbbVie | Reiterates: Outperform | $135 | $171.73 | -21.39% | 1 | May 3, 2021 |
Verrica Pharmaceuticals
May 25, 2022
Downgrades: Sector Perform
Price Target: $16 → $4
Current: $0.99
Upside: +304.04%
Pfizer
Jun 17, 2021
Maintains: Sector Perform
Price Target: $43 → $44
Current: $25.13
Upside: +75.09%
MannKind
May 14, 2021
Initiates: Sector Perform
Price Target: $5
Current: $6.90
Upside: -27.54%
AbbVie
May 3, 2021
Reiterates: Outperform
Price Target: $135
Current: $171.73
Upside: -21.39%